Clinical trials: Stem Cell Transplants
Total-body Irradiation, Hematopoietic Stem Cell Transplant
Radiation Biodosimetry in Children Undergoing Total Body Irradiation
The purpose of this study is to develop fecal tests that will determine the extent of radiation exposure in patients undergoing radiation treatment for cancer.
- Trial name
- NCT01337648
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Medical College of Wisconsin
Multiple Myeloma, CLL
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
This study seeks to examine the investigational use of the conditioning regimen (bendamustine, fludarabine, and rituximab) prior to haploidentical peripheral blood allogeneic stem cell transplantation with Post-Transplant…
- Conditions
- Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma
- Trial name
- NCT03524235
- Testing
- Total Body Irradiation, Haploidentical Stem Cell Transplantation, CD56-Enriched Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Noah Merin
Hematopoietic Stem Cell Transplant, Pediatric Cancer
Benefits of Intrahospital Exercise Program in Pediatric HSCT
This randomized control study examines the effect of an intrahospital exercise regimen on the physical deconditioning that occurs due to hematopoietic stem cell transplant in the pediatric population.
- Conditions
- Hematopoietic Stem Cell Transplant, Pediatric Cancer, Deconditioning
- Trial name
- NCT06692478
- Testing
- Exercise regimen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Phoenix Children's Hospital
Myelodysplastic Syndromes (MDS)
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Alvocidib, a cyclin-dependent kinase 9 (CDK 9) inhibitor, in time-sequential therapy demonstrated significant clinical activity in secondary AML patients with prior MDS.
- Trial name
- NCT03593915
- Testing
- Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine
- Where
- 12 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sumitomo Pharma America, Inc.
Nutrition Aspect of Cancer, Stem Cell Transplant Complications
Study on Intelligent Nutrition Support Therapy for Hematopoietic Stem Cell Transplantation Recipients
The use of high-dose radiotherapy, chemotherapy and preventive antibiotics in the preconditioning regimen before allogeneic hematopoietic stem cell transplantation can easily lead to damage to the gastrointestinal mucosa…
- Trial name
- NCT05590091
- Testing
- Parenteral nutrition;Enteral nutrition
- Volunteers
- 106 people
- Sponsor
- Hebei Yanda Ludaopei Hospital
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
This is a single arm, open-label, Phase 1b study of pembrolizumab for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) whose disease has relapsed after receiving…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03286114
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection
Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
HLH, HLH-related disorders, Chronic Granulomatous (CGD), HIGM1, Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX) and severe LAD-I represent primary immune disorders that are typically fatal…
- Conditions
- Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1
- Trial name
- RICHI (NCT01998633)
- Testing
- Hematopoietic Stem Cell Transplant
- Where
- 22 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Medical College of Wisconsin
Limbus Corneae Insufficiency Syndrome
Safety Study of Stem Cell Transplant to Treat Limbus Insufficiency Syndrome
The purpose of the study is to determine whether allogenic bone marrow stem cell transplant is safe and effective in the treatment of limbus insufficiency syndrome versus allogenic limbus stem cell transplant.
- Trial name
- NCT01562002
- Testing
- Stem Cell with Amniotic Membrane Transplant
- Where
- Spain
- Volunteers
- 27 people
- Sponsor
- Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
Non-hodgkin Lymphoma
Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma
The purpose of this study is to determine the correct dose and safety of adding a new cancer drug, Venetoclax, to a standard combination of chemotherapy drugs used prior to Autologous stem cell transplant (ASCT) in participants…
- Trial name
- NCT03713580
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
Refractory Plasma Cell Myeloma
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
This phase II trial studies the side-effects and anti-cancer effects of giving an autologous or syngeneic stem cell transplant followed by an allogeneic donor stem cell transplant and bortezomib.
- Trial name
- NCT00793572
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Cyclosporine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004088
- Testing
- filgrastim, recombinant interferon alfa, busulfan
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- City of Hope Medical Center
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Leukemia, Relapse
Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia
The purpose of this study is to evaluate the efficacy and safety of sorafenib maintenance after allo-HSCT in FLT3-negative acute leukemia patients.
- Conditions
- Acute Leukemia, Relapse, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT04674345
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hodgkin's Lymphoma
Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients
Test of bendamustine in combination with gemcitabine and vinorelbine could contribute to a higher response rate with the reduction of toxic side effects
- Trial name
- NCT01884441
- Testing
- Bendamustine, Gemcitabine, Vinorelbine
- Where
- Italy
- Volunteers
- 59 people
- Sponsor
- Armando Santoro, MD
Multiple Myeloma
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
The purpose of this trial is to assess the immune response after vaccination with a peptide vaccine called galinpepimut-S (or GPS) in a type of blood cancer called multiple myeloma.
- Trial name
- NCT01827137
- Testing
- Galinpepimut-S, GM-CSF, Montanide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sellas Life Sciences Group
Lymphoma
GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant helps stop the growth of cancer cells by stopping them from dividing or by killing them.
- Trial name
- NCT00521014
- Testing
- filgrastim, rituximab, sargramostim
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.
- Trial name
- NCT03652064
- Testing
- Daratumumab, Bortezomib, Lenalidomide
- Where
- 114 sites in United States, Brazil and 11 more
- Volunteers
- 395 people
- Sponsor
- Janssen Research & Development, LLC
Sickle Cell Disease, Thalassemia
Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells
This is a clinical trial of bone marrow transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor.
- Conditions
- Sickle Cell Disease, Thalassemia, Anemia, Granuloma
- Trial name
- NCT00730314
- Testing
- Hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Children's Hospital Los Angeles
Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
This phase II trial tests how well ibrutinib works in preventing chronic graft-versus-host disease (GVHD) in patients undergoing donor (allogeneic) hematopoietic cell transplantation (HCT).
- Trial name
- NCT06271616
- Testing
- Echocardiography Test, Ibrutinib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Bone Marrow Transplantation
Fecal Microbiota Transplantation After HSCT
This research study is studying an intervention called fecal microbiota transplantation (FMT). Patients who are scheduled to undergo Hematopoietic Stem Cell Transplantation are invited to take part in this clinical trial to…
- Trial name
- NCT02733744
- Testing
- Fecal Microbiota Transplantation (FMT)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.